NLRP3 Inflammasome: A New Therapeutic Target for High-Risk Reproductive Disorders?
The NOD-like receptor protein 3 (NLRP3) inflammasome is a critical component of the innate immune system, playing a pivotal role in the host’s defense against pathogens and stress-related endogenous signals. It is primarily expressed and activated in immune cells such as dendritic cells and macrophages, where it regulates the production of pro-inflammatory cytokines. The NLRP3 inflammasome has been implicated in a wide range of immune and metabolic disorders, including atherosclerosis, gout, kidney disease, obesity, type 2 diabetes, and inflammatory bowel disease. Recent research has also highlighted its involvement in various high-risk reproductive disorders, such as endometriosis, polycystic ovary syndrome (PCOS), recurrent spontaneous abortion (RSA), preterm birth, pre-eclampsia (PE), and gestational diabetes mellitus (GDM). This article provides a comprehensive review of the role of the NLRP3 inflammasome in these reproductive disorders, exploring its mechanisms of activation, its involvement in disease pathogenesis, and its potential as a therapeutic target.
Mechanism of NLRP3 Activation
The NLRP3 inflammasome is a multi-protein complex that belongs to the nucleotide-binding oligomerization domain, leucine-rich repeat (LRR)-containing protein family. It consists of three main components: a central nucleotide-binding and oligomerization domain, a C-terminal LRR domain, and an N-terminal pyrin domain. The activation of the NLRP3 inflammasome is a two-step process. The first step, known as the priming signal, involves the upregulation of NLRP3 and pro-interleukin (IL)-1β and pro-IL-18 expression in response to stimuli such as lipopolysaccharide (LPS). The second step, the activation signal, is triggered by various endogenous and exogenous stimuli, including cholesterol crystals, uric acid, ATP, asbestos, ultraviolet light, and pathogenic microorganisms. During this step, the C-terminal LRR domain senses these stimuli and binds to the pyrin domain of the adaptor protein ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain). This interaction recruits pro-caspase-1, which undergoes self-cleavage to form the active caspase-1 complex. Active caspase-1 then cleaves pro-IL-1β and pro-IL-18 into their mature forms, IL-1β and IL-18, which are secreted from the cell to initiate downstream inflammatory responses.
The precise mechanisms underlying NLRP3 inflammasome activation remain incompletely understood. However, several processes have been proposed, including changes in intracellular calcium concentration, lysosomal damage, mitochondrial dysfunction, potassium ion efflux, and reactive oxygen species (ROS) production. The primary function of the NLRP3 inflammasome is to assemble the inflammatory complex, with ASC serving as the adaptor protein that connects NLRP3 to caspase-1. Overactivation of the NLRP3 inflammasome can lead to pyroptosis, a form of programmed cell death characterized by the excessive release of inflammatory cytokines, which contributes to the pathogenesis of various diseases.
NLRP3 and Reproductive Disorders
NLRP3 and Endometriosis
Endometriosis (EMs) is a common gynecological disorder affecting 10-15% of women of reproductive age and up to 30% of infertile women. The disease is characterized by the growth of endometrial tissue outside the uterus, leading to chronic inflammation and pain. Recent studies have suggested that immune dysregulation and inflammation play a central role in the pathogenesis of EMs. Women with EMs often exhibit comorbidities such as hypothyroidism, autoimmune diseases, fibromyalgia, and chronic fatigue syndrome, suggesting a potential link between endometriosis and autoimmunity.
The peritoneal fluid of women with EMs contains defective macrophages and natural killer (NK) cells, which fail to clear ectopic endometrial cells effectively. These macrophages secrete various inflammatory mediators, including growth factors, enzymes, prostaglandins, and cytokines, which promote the adhesion and proliferation of endometrial tissue in ectopic sites. The NLRP3 inflammasome has been implicated in the inflammatory response associated with EMs. Studies have shown that the levels of NLRP3, caspase-1, and IL-18 are upregulated in ectopic endometrial tissues, and the concentrations of IL-1β in the peritoneal fluid of women with EMs are significantly higher than in healthy controls. IL-1β is known to upregulate the expression of cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF), which contribute to the development of EMs.
Animal models of EMs have demonstrated that the inhibition of NLRP3 reduces the production of inflammatory cytokines, suggesting that targeting the NLRP3 inflammasome could be a potential therapeutic strategy for EMs. For example, silencing the oncogene Astrocyte elevated gene-1 (AEG-1) has been shown to inhibit the formation of the NLRP3 inflammasome and reduce inflammation in EMs. However, further research is needed to explore the efficacy of NLRP3 inhibitors in the treatment of EMs.
NLRP3 and Polycystic Ovary Syndrome (PCOS)
PCOS is a common endocrine and metabolic disorder affecting women of reproductive age. It is associated with hyperandrogenism, insulin resistance, obesity, metabolic syndrome, and reproductive abnormalities. Chronic low-grade inflammation has been proposed as a key factor in the pathogenesis of PCOS. Women with PCOS exhibit elevated levels of inflammatory cytokines such as IL-1β, IL-6, TNF-α, and monocyte chemoattractant protein-1 (MCP-1) in their peripheral blood.
The NLRP3 inflammasome has been implicated in the inflammatory response associated with PCOS. Hyperandrogenism, a hallmark of PCOS, has been shown to drive the activation of the NLRP3 inflammasome, leading to the secretion of inflammatory mediators and the development of ovarian fibrosis. Ovarian fibrosis is characterized by increased cystic follicles, a thickened thecal cell layer, and reduced corpus luteum formation, which are commonly observed in women with PCOS. Inhibition of the NLRP3 inflammasome using specific inhibitors such as INF39 has been shown to reduce ovarian fibrosis and improve follicular development in animal models of PCOS.
IL-1β, a key cytokine produced by the NLRP3 inflammasome, plays a role in the development of insulin resistance and obesity, which are common features of PCOS. IL-1β impairs insulin signaling in adipose tissue and stimulates lipolysis, contributing to weight gain. The pioglitazone metformin complex, a treatment for PCOS, has been shown to inhibit NLRP3 inflammasome activation and reduce IL-1β levels, highlighting the potential of targeting the NLRP3 inflammasome in the management of PCOS.
NLRP3 and Recurrent Spontaneous Abortion (RSA)
RSA, defined as the occurrence of three or more consecutive miscarriages, is a complex condition with multiple etiologies, including anatomical, endocrine, genetic, immune, and infectious factors. Immune dysregulation and inflammation at the maternal-fetal interface have been proposed as key factors in the pathogenesis of RSA. The NLRP3 inflammasome has been shown to be upregulated in the endometrial tissues of women with RSA, leading to the secretion of IL-1β and IL-18, which disrupt the balance of anti- and pro-inflammatory factors necessary for maintaining pregnancy.
Studies have shown that the activation of the NLRP3 inflammasome in trophoblast cells, triggered by factors such as palmitic acid and antiphospholipid antibodies, contributes to the inflammatory response associated with RSA. The NLRP3 inflammasome also regulates the balance between regulatory T (Treg) cells and Th17 cells, which play a critical role in the pathogenesis of RSA. Inhibitors of the NLRP3 inflammasome, such as MCC950 and beta-hydroxybutyrate, have shown promise in reducing inflammation and improving pregnancy outcomes in animal models of RSA. However, further research is needed to evaluate the safety and efficacy of these inhibitors in clinical settings.
NLRP3 and Preterm Birth
Preterm birth, defined as delivery before 37 weeks of gestation, is a leading cause of neonatal morbidity and mortality. Intra-amniotic inflammation and infection are the most common causes of spontaneous preterm labor. The NLRP3 inflammasome is expressed in pregnancy-related tissues such as the uterus, fetal membranes, and placenta, and its activation has been implicated in the pathogenesis of preterm birth.
Studies have shown that the NLRP3 inflammasome is activated in the fetal membranes of women with spontaneous preterm labor and acute chorioamnionitis, leading to the secretion of IL-1β and IL-18. These cytokines promote the production of prostaglandins, which are key regulators of cervical ripening and uterine contractions. Inhibition of the NLRP3 inflammasome using specific inhibitors such as MCC950 has been shown to prevent preterm labor and improve neonatal outcomes in animal models. However, the inhibition of the NLRP3 inflammasome at term does not interfere with the physiological process of parturition, suggesting that targeting the NLRP3 inflammasome could be a safe and effective strategy for preventing preterm birth.
NLRP3 and Pre-eclampsia (PE)
PE is a pregnancy-specific syndrome characterized by hypertension, proteinuria, and fetal intrauterine growth restriction. The pathogenesis of PE involves inflammation and immune activation, with the placenta playing a central role. The NLRP3 inflammasome is upregulated in the placentas of women with PE, leading to the secretion of IL-1β and IL-18, which contribute to the inflammatory response and endothelial dysfunction associated with PE.
Several endogenous danger/damage-associated molecular patterns (DAMPs), such as cholesterol crystals, uric acid, and extracellular DNA, have been shown to activate the NLRP3 inflammasome in PE. These DAMPs induce lysosomal rupture, potassium efflux, and mitochondrial damage, leading to the activation of the NLRP3 inflammasome. Inhibitors of the NLRP3 inflammasome, such as MCC950 and allopurinol, have shown promise in reducing inflammation and improving pregnancy outcomes in animal models of PE. However, further research is needed to evaluate the safety and efficacy of these inhibitors in clinical settings.
NLRP3 and Gestational Diabetes Mellitus (GDM)
GDM is a metabolic disorder characterized by glucose intolerance during pregnancy. It is associated with adverse pregnancy outcomes and long-term health risks for both the mother and the offspring. The NLRP3 inflammasome has been implicated in the pathogenesis of GDM, with studies showing that hyperglycemia activates the NLRP3 inflammasome and increases the secretion of IL-1β and IL-18 in placental tissues.
Chronic inflammation and insulin resistance are key features of GDM, and the NLRP3 inflammasome plays a central role in these processes. Inhibitors of the NLRP3 inflammasome, such as glyburide and astragaloside IV, have shown promise in reducing inflammation and improving glucose tolerance in animal models of GDM. However, further research is needed to evaluate the safety and efficacy of these inhibitors in clinical settings.
Conclusion
The NLRP3 inflammasome plays a critical role in the pathogenesis of various high-risk reproductive disorders, including endometriosis, PCOS, RSA, preterm birth, PE, and GDM. Its activation leads to the secretion of pro-inflammatory cytokines, which contribute to the inflammatory response and tissue damage associated with these conditions. Targeting the NLRP3 inflammasome represents a promising therapeutic strategy for the prevention and treatment of these disorders. However, further research is needed to fully understand the mechanisms underlying NLRP3 inflammasome activation and to develop safe and effective inhibitors for clinical use.
doi.org/10.1097/CM9.0000000000001214
Was this helpful?
0 / 0